XMVA09

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug NameXMVA09
Drug Alias NameXMVA-09XMVA-09 (AAV载体基因治疗药物)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV-RPE vector
Mechanisms of ActionAnti-Vascular endothelial growth factorAnti-Angiopoietin-2
TargetsVascular endothelial growth factorAngiopoietin-2
Therapy Area/IndicationsDiabetic macular oedemaWet age-related macular degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesStarry Gene
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesStarry GeneGuangzhou Packgene Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaWet age-related macular degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A